MEDVi vs SHED: Which GLP-1 Program Fits You Better in 2026?

The bottom line on MEDVi vs SHED

If you're comparing MEDVi vs SHED for a GLP-1 program, here's the straight answer: MEDVi wins if you want the lowest first-month price on a compounded semaglutide injection ($179), refills MEDVi states are locked at $299/month, and the freedom to cancel month-to-month. SHED wins if you want needle-free options like sublingual drops or lozenges, the broadest medication menu of any cash-pay GLP-1 platform we've reviewed, or all-50-state public availability — at the cost of a two-month minimum commitment.

Most comparison pages stop there and call it a tie. We're not going to. Below we run the actual cost math, decode the cancellation fine print neither provider puts on its landing page, surface the FDA warning letter MEDVi received in February 2026 (and what it actually says), and end with a fit-by-situation pick — because the right answer depends on whether you hate needles, plan to escalate your dose, or can swallow a two-month commitment.

MEDVi vs SHED at a glance

MEDVi is a focused compounded GLP-1 platform with the lowest verified entry price on semaglutide injections and refills MEDVi states are locked at $299/month. SHED is a broader compounded GLP-1 platform offering injections, sublingual drops, dissolvable lozenges, oral liposomal tablets, and a brand-name membership path — at the cost of a two-month minimum commitment.

What we actually verified before writing this comparison

Every commercial fact on this page was verified against each provider's official site, help center, or legal terms — not summarized from press releases or sponsor copy. Where a number depends on dose tier, program, or state, we've labeled it. If a price you see at checkout differs from what's here, the checkout price is current.

We're transparent about what we checked because most GLP-1 comparison pages aren't. The sources:

• MEDVi: the GLP-1 product page (glp.medvi.org), the cancellation and refund policy, the terms and conditions, the public Trustpilot profile (medvi.org), and FDA Warning Letter #721455 issued February 20, 2026.
• SHED: the main pricing page (tryshed.com), the Shed Help Center pages on subscription pricing, brand-name access, FSA/HSA, shipping, and cancellation, plus the legal terms of service and the Trustpilot profile (tryshed.com).
• FDA: the FDA Warning Letter database, the FDA's stated concerns about unapproved GLP-1 drugs used for weight loss, and the April 1, 2026 approval announcement for Foundayo (orforglipron).
• Cross-reference: ConsumerAffairs profiles, Vaccine Alliance, AccessNewswire, U.S. News & World Report, and Fierce Healthcare.

Last verified: April 24, 2026. This page is on a quarterly re-verification cadence at minimum, and is re-checked any time either provider changes pricing, formulary, or policy.

The full MEDVi vs SHED comparison

Across pricing, format selection, cancellation, pharmacy disclosure, and regulatory status, MEDVi and SHED look more different on close inspection than they do in ads. The table below is the complete side-by-side — if you read nothing else, read this.

Is MEDVi or SHED cheaper? The real cost math

At the entry semaglutide injection tier, MEDVi is cheaper for month one ($179 vs SHED's $199 starter). On refills, MEDVi states its semaglutide injection refill is locked at $299/month; SHED's price tiers run $199 (starter) to $299 (standard) per its Help Center. Year-1 totals depend on whether you stay at SHED's starter tier or escalate to standard, plus whether your specific SHED program bills every 28 days or monthly.

First-month price (apples to apples)

The takeaway: MEDVi has the cheapest semaglutide injection entry price and the cheapest oral tablet entry price. SHED has the cheapest tirzepatide injection entry price (per its public Help Center tier) and is the only one of the two with sublingual drops or lozenges.

The refill math nobody else does

MEDVi states its $299/month semaglutide refill is locked. SHED's Help Center publishes a tier ladder where the standard semaglutide injection sits at $299/month, the starter tier at $199, and a microdose tier at $149 (microdose is a clinical decision your provider has to confirm).

If your dose moves from starter to standard — which most patients do over six to nine months — SHED's $299 standard meets MEDVi's $299. If you can stay at the starter tier longer, SHED stays cheaper. The microdose tier at $149/month is real, but it isn't the right clinical fit for most weight-loss patients targeting therapeutic dosing.

Year-1 total cost, semaglutide injection

MEDVi's refund policy describes the program as a subscription that automatically renews every 28 days, which means roughly 13 billing cycles per year rather than 12. SHED's terms reference 28-day or monthly billing depending on program — verify your specific cycle at checkout.

Bottom line on price: SHED is cheaper if you stay at the starter tier. MEDVi gives you a single number to budget against because its refill is locked. For most patients heading toward therapeutic dosing within six months, the year-1 difference narrows enough that other factors — format, cancellation tolerance, transparency — should drive the choice.

Which one has the better GLP-1 medication options?

SHED offers the broader medication menu — injections, sublingual drops, dissolvable lozenges, oral liposomal tablets, and a brand-name membership pathway. MEDVi offers a tighter, simpler menu — injections, oral tablets, and a brand-name membership path. If format flexibility matters, SHED wins; if focus and predictability matter, MEDVi wins.

Compounded semaglutide injections — both offer

Both providers facilitate access to weekly compounded semaglutide injections through licensed pharmacy partners. MEDVi names Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding on its main GLP-1 page; SHED names Strive Compounding Pharmacy, Promise Pharmacy, and Foothills Professional Pharmacy in its terms. Winner on price: MEDVi at $179 first month / $299 locked refill. SHED at $199 first month / $199–$299 depending on tier.

Compounded tirzepatide injections — both offer

Tirzepatide is a dual GLP-1 / GIP receptor agonist. The FDA-approved branded versions (Mounjaro and Zepbound, manufactured by Eli Lilly) showed meaningful weight loss in their pivotal SURMOUNT trials. Compounded tirzepatide is not the same as the FDA-approved versions and has not gone through FDA review. Winner on transparency: SHED publishes a clear tier ladder ($199 microdose / $299 starter / $399 standard) in its Help Center. MEDVi lists tirzepatide pricing around $349 in navigation; confirm your specific tier at checkout because patient reports show pricing can vary by dose.

Sublingual drops and dissolvable lozenges — SHED only

SHED offers two needle-free formats MEDVi doesn't sell: GLP-1 liquid drops at $229/month (taken under the tongue) and GLP-1 lozenges at $199/month (dissolved in the mouth).

Oral compounded tablets — both offer

MEDVi sells GLP-1 tablets from $249/month. SHED sells oral semaglutide liposomal tablets from $299/month. The same compounded-vs-FDA-approved disclosure and absorption considerations apply to both.

Brand-name (FDA-approved) pathways — both offer, but neither is the strongest fit

• MEDVi charges $99/month for a membership; medication purchased separately. Lists Wegovy pill, Wegovy injection, and Zepbound injection.
• SHED charges $125/month; medication purchased via LillyDirect (Zepbound, Foundayo) or NovoCare (Wegovy).

Cancellation, refunds, and the fine print

MEDVi is easier to leave. It's month-to-month with 72-hour cancellation notice and no minimum commitment. SHED requires a two-month minimum before you can cancel at all, and then 72-hour notice. Neither offers automatic refunds for canceled cycles after the first paid bill, though both refund the first charge if a clinician determines you're not eligible.

This section catches more buyers off guard than any other. Read it before you pay either provider.

MEDVi: month-to-month, 72-hour notice

MEDVi's refund policy describes the program as a subscription that automatically renews every 28 days, with cancellation available at any time as long as the request lands at least 72 hours before your next billing date. There's no minimum commitment, no contract, no early-termination fee. If a licensed clinician determines you are not eligible, MEDVi issues a full refund. Outside of that medical-disqualification refund, the medication you've already been billed for is yours to keep.

SHED: two-month minimum, then 72-hour notice

SHED's terms of service state that all programs require a minimum commitment of two full months. Cancellation requests submitted during the first two months don't release you from payment for that second cycle. After the two-month minimum, the 72-hour notice rule applies the same way as MEDVi's. Subscription fees are nonrefundable once charged. SHED's terms also state that the brand-name membership fee is refunded if you are not approved by a licensed provider.

The two-month minimum is a real constraint and it should be visible to you before you enter payment. If you're the kind of buyer who wants to test one billing cycle and leave if it isn't right, MEDVi fits better.

The 28-day billing rhythm

MEDVi's policy is 28-day billing, which means roughly 13 cycles per calendar year, not 12. SHED's terms reference either 28-day or monthly billing depending on the specific program, so verify your billing interval at checkout. Either way, set a calendar event for four days before your next billing date — that gives you a one-day buffer over the 72-hour notice window. Both providers email you near the end of each cycle, but the message is easy to miss.

Pharmacy transparency — where your medication actually comes from

Both providers disclose pharmacy partners, but in different places. MEDVi names its three partner pharmacies on the main GLP-1 product page; SHED names its three partner pharmacies in its legal terms. SHED's terms also include a broader caveat that medications may be sourced from outside the U.S.

This matters because compounded medications are only as safe as the pharmacy producing them. Compounding may occur under Section 503A (state-licensed traditional compounding for individual prescriptions) or Section 503B (federally registered outsourcing facilities under stricter manufacturing standards) of the Federal Food, Drug, and Cosmetic Act, depending on the pharmacy and circumstances.

Honestly, both could be more public about pharmacy disclosure. MEDVi puts pharmacy names on the main product page, which is industry-leading transparency. SHED tucks the names into legal terms, which is industry-standard but less visible. Neither provider routinely publishes Certificates of Analysis (COAs) for medication batches, which would be the gold standard for compounded-medication transparency.

The MEDVi FDA warning letter — what it says, what it means

In February 2026, the FDA issued MEDVi Warning Letter #721455, citing concerns about marketing claims and product representations on MEDVi's website. The letter targeted how MEDVi described compounded semaglutide and tirzepatide products to consumers, not the safety of the medications themselves. MEDVi continues to operate.

What this means practically

If transparency in marketing language is critical to you — and we think it should be — this is a real disclosure point. MEDVi has had to revise marketing claims to come into compliance. Other compounded GLP-1 providers have received similar letters as the FDA has tightened scrutiny of mass-marketed compounded products since 2024.

If MEDVi's clinical operation, named pharmacy partners, Trustpilot rating (4.4/5 across 13,000+ reviews), and month-to-month flexibility outweigh the marketing-claim issue for you, MEDVi is still a legitimate option for cash-pay GLP-1 access. If the warning letter is a dealbreaker for you specifically, SHED is the alternative — no SHED FDA warning letter was found in our April 24, 2026 search — and SHED carries the same medication classes through licensed pharmacy partners.

The damaging admission — and why most readers should still do this

Both MEDVi and SHED facilitate access to compounded GLP-1 medications. Compounded drugs are not FDA-approved finished products and are not individually evaluated by the FDA for safety, effectiveness, or quality before marketing. If FDA-approved as a finished product is your minimum standard, neither MEDVi nor SHED is the right fit.

We're going to be straight with you because we'd rather lose you here than have you regret a $200/month subscription you didn't fully understand.

Because MEDVi and SHED skip the brand-name overhead, they can deliver compounded GLP-1 access starting at $179/month (MEDVi) or $149/month (SHED microdose) — roughly 80–90% less than the $1,000–$1,500/month list price of brand-name versions. MEDVi states 500,000+ patients on its current GLP-1 page; SHED states 150,000+ success stories. That scale is why we keep both in our recommendation set even though we surface the FDA-approval distinction every time.

Is MEDVi or SHED available in my state?

SHED's Help Center publicly confirms availability in all 50 U.S. states (excluding Puerto Rico). MEDVi serves most states, but its terms instruct readers to confirm the current state list with customer service. Some states require a video visit before prescribing.

Does MEDVi or SHED accept HSA / FSA?

Both providers accept HSA and FSA cards at checkout for prescription purchases. Coaching add-ons and supplements may not always be HSA/FSA eligible — confirm with your plan administrator. HSA/FSA dollars are pre-tax, which can meaningfully reduce your real cost.

• MEDVi advertises "HSA/FSA Approved" on its GLP-1 product page.
• SHED's Help Center confirms HSA/FSA cards are accepted for prescription purchases and recommends confirming eligibility with your account administrator. SHED specifically notes that coaching and supplements may require additional documentation or may not qualify.

If you have HSA/FSA dollars sitting unused, this is one of the cleanest ways to use them on weight management. The exact tax savings depend on your federal and state marginal rates, payroll tax treatment, and plan rules — your benefits administrator or tax professional can give you a precise number.

Does MEDVi or SHED take insurance?

Neither provider bills insurance for compounded medications. MEDVi notes some insurance reimbursement may be possible for branded medications; SHED's terms state insurance may not be accepted for its services. If insurance coverage is your priority, Ro is the better path.

If insurance coverage is critical to your decision — and especially if your employer plan covers brand-name Wegovy or Zepbound — skip both compounded paths and use Ro's GLP-1 Insurance Coverage Checker to see what your plan will pay before you commit to anything. Ro's insurance concierge checks coverage, handles prior-authorization paperwork directly, and follows up with the insurer. That single feature is the biggest difference between Ro and the cash-pay-only platforms compared on this page.

MEDVi vs SHED reviews: what real customers are saying

Both providers have meaningful Trustpilot histories. MEDVi has higher review volume (13,000+) at a 4.4/5 rating; SHED has a higher score (4.7/5) on a smaller volume (893 reviews). The complaint patterns at both are similar — billing surprises and shipping delays.

None of these testimonials are presented as evidence of medical efficacy or typical results. Individual results vary. Weight loss with any GLP-1 depends on adherence, dose, lifestyle, and individual physiology.

Who should pick MEDVi

MEDVi is the better fit for buyers who want the lowest first-month price on a compounded semaglutide injection, locked refill pricing, true month-to-month flexibility, and named US pharmacy partners on the main product page. Pick MEDVi if you want simple, focused, and cash-pay-friendly.

You're a strong fit for MEDVi if any of these apply:

• ✓

  Cheapest verified first-month price

  You want the cheapest verified first-month price on a compounded semaglutide injection ($179) and are okay with the refill jump to $299/month after.

• ✓

  Locked refill pricing

  You want locked refill pricing. MEDVi states the $299/month refill is locked. SHED's tier ladder moves with your dose.

• ✓

  Test one billing cycle with the option to leave

  You want to test one billing cycle and have the option to leave. MEDVi has no two-month minimum. You can cancel after month one with 72-hour notice.

• ✓

  Pharmacy transparency on the main product page

  You care about pharmacy transparency on the main product page. MEDVi names Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding directly on the GLP-1 page.

• ✓

  FDA warning letter context is acceptable

  You're okay with the February 2026 FDA warning letter context (covered above) given MEDVi's broader review base, named US pharmacy partners, and clinical network.

• ✓

  Cheaper brand-name pathway later

  You want the cheaper brand-name pathway between these two if you decide to move to FDA-approved medication later — MEDVi's $99 membership is $26/month less than SHED's $125.

Who should pick SHED

SHED is the better fit for buyers who want needle-free formats (sublingual drops or dissolvable lozenges), the broadest medication-format menu in cash-pay GLP-1, public confirmation of all-50-state availability, or a 9-month weight-loss guarantee — and who can commit for at least two months.

You're a strong fit for SHED if any of these apply:

• ✓

  Needle-free options

  You want needle-free options. SHED has $229/month sublingual drops and $199/month lozenges. MEDVi doesn't sell either format.

• ✓

  Broadest medication menu

  You want the broadest menu. SHED carries injections, drops, lozenges, oral liposomal tablets, and a brand-name membership pathway.

• ✓

  All-50-state public availability

  You want public confirmation that the provider operates in your state. SHED's Help Center publicly states all 50 U.S. states (excluding Puerto Rico).

• ✓

  9-month results guarantee

  You're motivated by a results guarantee and willing to follow the rules (weekly weigh-ins, monthly check-ins, Facebook group participation) for SHED's 10% weight-loss guarantee.

• ✓

  Two-month commitment is acceptable

  You can commit for two months. This is SHED's biggest constraint — do not pick SHED if you're not ready to commit through the second 28-day cycle.

• ✓

  Tirzepatide starter under $349

  You want a tirzepatide starter under $349. SHED's $299 starter tirzepatide tier (per its Help Center) is cheaper than MEDVi's listed tirzepatide pricing.

Who should skip both MEDVi and SHED

Both are operating compounded GLP-1 platforms but they're not the right answer for everyone. Skip both if you need FDA-approved brand-name medication, want insurance to cover the medication, can't tolerate any subscription auto-renewal risk, or want a hands-on local clinician relationship.

• →You want FDA-approved brand-name medication as a baseline — Wegovy, Zepbound, or Foundayo specifically. Compounded medications are not FDA-approved finished products. Go to Ro instead.
• →You need insurance to cover the medication. Neither provider bills insurance for compounded products. Ro's insurance concierge handles prior authorization for brand-name medication.
• →You're enrolled in Medicare or Medicaid and want guidance on coverage. Compounded GLP-1 platforms don't engage with public insurance. Talk to your prescribing physician.
• →You can't tolerate any subscription auto-renewal risk. Both providers operate on recurring billing. If this is a hard line, neither model fits — consider a single-fill prescription through a local provider.
• →You want a local in-person clinician doing labs, vitals, and follow-ups in person. Both MEDVi and SHED are telehealth.
• →You have a complex medical history that requires close clinical review before starting any GLP-1 — type 1 diabetes, history of pancreatitis, medullary thyroid carcinoma family history, certain GI conditions. A primary-care or endocrinology consult locally is the right starting point.
• →You're shopping primarily on price and a different provider might fit your budget better than either of these two.

Final verdict on MEDVi vs SHED

Pick MEDVi for the lowest first-month semaglutide injection price, locked refill predictability, and month-to-month cancellation. Pick SHED for needle-free formats, the broadest menu, and all-50-state public availability — if you can accept a two-month commitment. Pick neither if FDA-approved brand-name medication is your priority — go with Ro.

If you've read this far and still aren't sure, that's a signal that one of three things is true: you're on the fence between cost and format, you want insurance involved, or you need clinical input before you can decide. The matching quiz handles all three in about 60 seconds.

How we evaluated MEDVi vs SHED

Our evaluation framework weights the buyer-relevant friction points: pricing clarity, medication-format fit, cancellation, pharmacy transparency, state and HSA/FSA access, customer reviews, and regulatory signals. We don't crown a global winner — we crown situational winners, because the right answer depends on the reader.

Applying that framework produces situational winners, not a single ranked output:

Both are real recommendations. We don't write a single "winner" headline because the question "which is better?" doesn't have a single answer when both providers are good at different things.

Frequently asked questions about MEDVi vs SHED

What we verified before publishing

Refresh cadence: This page is re-verified at least quarterly and any time either provider changes pricing, formulary, or policy. If a price or fact on this page differs from what you see at the provider's checkout, the checkout price is correct — let us know and we'll update.